Delays in breast cancer presentation, diagnosis, and treatment in young women

IF 5.6 2区 医学 Q1 ONCOLOGY
Cancer Pub Date : 2026-10-12 DOI:10.1002/cncr.70594
Bessie X. Zhang MD, MBA, Tal Sella MD, Yue Zheng MS, Gregory J. Kirkner MPH, Kathryn J. Ruddy MD, MPH, Shoshana M. Rosenberg ScD, MPH, Virginia F. Borges MD, MMSc, Lidia Schapira MD, Steven E. Come MD, Jeffrey M. Peppercorn MD, MPH, Laura Collins MD, Ann H. Partridge MD, MPH, Kristen D. Brantley PhD, MPH
{"title":"Delays in breast cancer presentation, diagnosis, and treatment in young women","authors":"Bessie X. Zhang MD, MBA,&nbsp;Tal Sella MD,&nbsp;Yue Zheng MS,&nbsp;Gregory J. Kirkner MPH,&nbsp;Kathryn J. Ruddy MD, MPH,&nbsp;Shoshana M. Rosenberg ScD, MPH,&nbsp;Virginia F. Borges MD, MMSc,&nbsp;Lidia Schapira MD,&nbsp;Steven E. Come MD,&nbsp;Jeffrey M. Peppercorn MD, MPH,&nbsp;Laura Collins MD,&nbsp;Ann H. Partridge MD, MPH,&nbsp;Kristen D. Brantley PhD, MPH","doi":"10.1002/cncr.70594","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Breast cancer (BC) in young patients is often identified at later stages, which can result in poor prognosis. It is important to investigate the factors influencing care delays and how delays affect outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study included women aged ≤40 years at diagnosis of stage 0–IV BC in the Young Women’s Breast Cancer Study enrolled between 2006 and 2016. Associations between patient and tumor factors and presentation delay (first symptom to provider visit, ≥90 days), diagnostic delay (presentation to diagnosis, ≥90 days), and treatment delay (diagnosis to treatment, ≥60 days) were estimated via logistic regression. Multivariable logistic models for delays were constructed via backward selection (<i>p</i> ≤ .05 retained). Multivariable Cox proportional hazards models tested the association between delays and disease-free survival (DFS) and overall survival (OS). Analyses were stratified by tumor subtype and stage.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 1071 women, there were 153 presentation, 120 diagnostic, and 228 treatment delays. In multivariable models, lower annual income was associated with higher odds of presentation delay, whereas pregnancy at diagnosis, family history of BC, and triple-negative (TN) subtype were associated with lower odds. In HER2-positive luminal B tumors, presentation delays were associated with later stage (<i>p</i> &lt; .001). Odds of diagnostic delay were higher for younger patients and lower for those with TN tumors. Patients with more aggressive tumor subtypes were less likely to have treatment delays. Delays were not associated with DFS or OS.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In this cohort of young patients with BC, demographic and tumor factors were associated with delays in care. It is reassuring that delays did not influence disease outcomes.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 20","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.70594","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Breast cancer (BC) in young patients is often identified at later stages, which can result in poor prognosis. It is important to investigate the factors influencing care delays and how delays affect outcomes.

Methods

This study included women aged ≤40 years at diagnosis of stage 0–IV BC in the Young Women’s Breast Cancer Study enrolled between 2006 and 2016. Associations between patient and tumor factors and presentation delay (first symptom to provider visit, ≥90 days), diagnostic delay (presentation to diagnosis, ≥90 days), and treatment delay (diagnosis to treatment, ≥60 days) were estimated via logistic regression. Multivariable logistic models for delays were constructed via backward selection (p ≤ .05 retained). Multivariable Cox proportional hazards models tested the association between delays and disease-free survival (DFS) and overall survival (OS). Analyses were stratified by tumor subtype and stage.

Results

Among 1071 women, there were 153 presentation, 120 diagnostic, and 228 treatment delays. In multivariable models, lower annual income was associated with higher odds of presentation delay, whereas pregnancy at diagnosis, family history of BC, and triple-negative (TN) subtype were associated with lower odds. In HER2-positive luminal B tumors, presentation delays were associated with later stage (p < .001). Odds of diagnostic delay were higher for younger patients and lower for those with TN tumors. Patients with more aggressive tumor subtypes were less likely to have treatment delays. Delays were not associated with DFS or OS.

Conclusions

In this cohort of young patients with BC, demographic and tumor factors were associated with delays in care. It is reassuring that delays did not influence disease outcomes.

年轻女性乳腺癌的表现、诊断和治疗延迟。
背景:年轻患者的乳腺癌(BC)通常在晚期才被发现,这可能导致预后不良。重要的是调查影响护理延误的因素以及延误如何影响结果。方法:本研究纳入了2006年至2016年纳入的年轻女性乳腺癌研究中诊断为0-IV期BC的年龄≤40岁的女性。通过logistic回归估计患者和肿瘤因素与表现延迟(首次症状到就诊,≥90天)、诊断延迟(表现到诊断,≥90天)和治疗延迟(诊断到治疗,≥60天)之间的关系。通过逆向选择构建延迟的多变量logistic模型(p≤0.05保留)。多变量Cox比例风险模型检验了延迟与无病生存期(DFS)和总生存期(OS)之间的关系。根据肿瘤亚型和分期进行分析。结果:在1071名妇女中,有153名出现,120名诊断,228名治疗延误。在多变量模型中,较低的年收入与较高的延迟出现几率相关,而诊断时怀孕、BC家族史和三阴性(TN)亚型与较低的延迟出现几率相关。在her2阳性腔内B肿瘤中,表现延迟与晚期相关(p结论:在这组年轻BC患者中,人口统计学和肿瘤因素与治疗延迟相关。令人欣慰的是,延误没有影响疾病的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书